$XBI $145.89 -2% 📉
Want to access our searchable database of over 900 catalysts and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA +9% Doses first patient in ph 2/3 study of covid vaccine in pediatric population. source
Pipeline Updates
$AVXL +9% Ph 3 results of ANAVEX 2-73 in neurodegenerative disorders published in journal of Neuropharmacology. source
$SPPI -4% FDA scheduled a pre-approval inspection of their ROLONTIS manufacturing facility in South Korea in May 2021. In Oct 2020 FDA deferred decision on BLA because inspection could not be conducted due to covid-19 travel restrictions. source
$FGEN -2% Initiate LELANTOS-2, 2nd ph 3 study of pamrevlumab for Duchenne muscular dystrophy. source
$GBT -4% In-licenses 2 early-stage sickle cell disease assets from Sanofi. Mechanism differentiated from Vox support the companies strategy to address SCD. source
$KALA +4% Cigna adds EYSUVIUS 0.25% as a preferred brand on it's commercial formulary. source
$KDNY -7% First patient dosed in ph 3 study of atrasentan for IGA nephropathy. source